Standardize the diagnosis and treatment of drug-induced liver injury, and strengthen clinical and translational research.
10.3760/cma.j.cn501113-20230419-00176
- Author:
Yi Min MAO
1
Author Information
1. Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Research Center of Fatty Liver Disease, Shanghai 200001, China.
- Publication Type:Journal Article
- Keywords:
Drug-related liver injury;
Guidelines;
Translational research
- MeSH:
Humans;
Translational Research, Biomedical;
Chemical and Drug Induced Liver Injury/therapy*;
Liver Diseases;
Liver Function Tests
- From:
Chinese Journal of Hepatology
2023;31(4):337-338
- CountryChina
- Language:Chinese
-
Abstract:
As a liver disease with the most complex clinical phenotype, drug-induced liver injury (DILI) poses great challenges in diagnosis and management in clinical practice. Although guidelines based on the latest research advances can provide clinicians with guidance on the identification, diagnosis, and management of DILI, the overall level of evidence in this field is relatively low and high-level evidence is limited. Therefore, we should interpret guidelines with caution and look forward to more clinical and translational research to address the huge unmet clinical needs in DILI.
